Literature DB >> 22374979

Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.

Jessica A Fowler1, Gregory R Mundy, Seint T Lwin, Claire M Edwards.   

Abstract

The rapid progression of multiple myeloma is dependent upon cellular interactions within the bone marrow microenvironment. In vitro studies suggest that bone marrow stromal cells (BMSC) can promote myeloma growth and survival and osteolytic bone disease. However, it is not possible to recreate all cellular aspects of the bone marrow microenvironment in an in vitro system, and the contributions of BMSCs to myeloma pathogenesis in an intact, immune competent, in vivo system are unknown. To investigate this, we used a murine myeloma model that replicates many features of the human disease. Coinoculation of myeloma cells and a BMSC line, isolated from myeloma-permissive mice, into otherwise nonpermissive mice resulted in myeloma development, associated with tumor growth within bone marrow and osteolytic bone disease. In contrast, inoculation of myeloma cells alone did not result in myeloma. BMSCs inoculated alone induced osteoblast suppression, associated with an increase in serum concentrations of the Wnt signaling inhibitor, Dkk1. Dkk1 was highly expressed in BMSCs and in myeloma-permissive bone marrow. Knockdown of Dkk1 expression in BMSCs decreased their ability to promote myeloma and the associated bone disease in mice. Collectively, our results show novel roles of BMSCs and BMSC-derived Dkk1 in the pathogenesis of multiple myeloma in vivo. ©2012 AACR

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22374979      PMCID: PMC3775476          DOI: 10.1158/0008-5472.CAN-11-2067

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass.

Authors:  Frederic Morvan; Kim Boulukos; Philippe Clément-Lacroix; Sergio Roman Roman; Isabelle Suc-Royer; Béatrice Vayssière; Patrick Ammann; Patrick Martin; Sonia Pinho; Philippe Pognonec; Patrick Mollat; Christof Niehrs; Roland Baron; Georges Rawadi
Journal:  J Bone Miner Res       Date:  2006-06       Impact factor: 6.741

Review 2.  How Wnt signaling affects bone repair by mesenchymal stem cells from the bone marrow.

Authors:  Carl A Gregory; William G Gunn; Emigdio Reyes; Angela J Smolarz; James Munoz; Jeffrey L Spees; Darwin J Prockop
Journal:  Ann N Y Acad Sci       Date:  2005-05       Impact factor: 5.691

3.  Malignant transformation in a nontumorigenic human prostatic epithelial cell line.

Authors:  S W Hayward; Y Wang; M Cao; Y K Hom; B Zhang; G D Grossfeld; D Sudilovsky; G R Cunha
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

4.  Animal model of human disease. Multiple myeloma.

Authors:  J Radl; J W Croese; C Zurcher; M H Van den Enden-Vieveen; A M de Leeuw
Journal:  Am J Pathol       Date:  1988-09       Impact factor: 4.307

5.  Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation.

Authors:  Simona Parrinello; Jean-Philippe Coppe; Ana Krtolica; Judith Campisi
Journal:  J Cell Sci       Date:  2005-01-18       Impact factor: 5.285

6.  Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion.

Authors:  Akira Orimo; Piyush B Gupta; Dennis C Sgroi; Fernando Arenzana-Seisdedos; Thierry Delaunay; Rizwan Naeem; Vincent J Carey; Andrea L Richardson; Robert A Weinberg
Journal:  Cell       Date:  2005-05-06       Impact factor: 41.582

7.  Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.

Authors:  S L Dallas; I R Garrett; B O Oyajobi; M R Dallas; B F Boyce; F Bauss; J Radl; G R Mundy
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

8.  TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia.

Authors:  Neil A Bhowmick; Anna Chytil; David Plieth; Agnieszka E Gorska; Nancy Dumont; Scott Shappell; M Kay Washington; Eric G Neilson; Harold L Moses
Journal:  Science       Date:  2004-02-06       Impact factor: 47.728

9.  Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice.

Authors:  J Radl; E D De Glopper; H R Schuit; C Zurcher
Journal:  J Immunol       Date:  1979-02       Impact factor: 5.422

10.  Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia.

Authors:  Marc H G P Raaijmakers; Siddhartha Mukherjee; Shangqin Guo; Siyi Zhang; Tatsuya Kobayashi; Jesse A Schoonmaker; Benjamin L Ebert; Fatima Al-Shahrour; Robert P Hasserjian; Edward O Scadden; Zinmar Aung; Marc Matza; Matthias Merkenschlager; Charles Lin; Johanna M Rommens; David T Scadden
Journal:  Nature       Date:  2010-03-21       Impact factor: 49.962

View more
  34 in total

1.  Bone marrow stromal cells influence myeloma progression via Dkk1.

Authors: 
Journal:  Bonekey Rep       Date:  2012-05-09

2.  Preclinical animal models of multiple myeloma.

Authors:  Seint T Lwin; Claire M Edwards; Rebecca Silbermann
Journal:  Bonekey Rep       Date:  2016-02-03

Review 3.  The biology of cancer-related fatigue: a review of the literature.

Authors:  Leorey N Saligan; Karin Olson; Kristin Filler; David Larkin; Fiona Cramp; Sriram Yennurajalingam; Yennu Sriram; Carmen P Escalante; Auro del Giglio; Kord M Kober; Jayesh Kamath; Oxana Palesh; Karen Mustian
Journal:  Support Care Cancer       Date:  2015-05-15       Impact factor: 3.603

4.  The transcriptomic profile of CD138+ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged.

Authors:  Paola Storti; Luca Agnelli; Benedetta Dalla Palma; Katia Todoerti; Valentina Marchica; Fabrizio Accardi; Gabriella Sammarelli; Federica Deluca; Denise Toscani; Federica Costa; Emanuela Vicario; Giannalisa Todaro; Eugenia Martella; Antonino Neri; Nicola Giuliani
Journal:  Haematologica       Date:  2019-03-07       Impact factor: 9.941

5.  Diet-induced obesity promotes a myeloma-like condition in vivo.

Authors:  S T Lwin; S W Z Olechnowicz; J A Fowler; C M Edwards
Journal:  Leukemia       Date:  2014-10-07       Impact factor: 11.528

Review 6.  Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention.

Authors:  Fuling Zhou; Shan Meng; Huanjin Song; François X Claret
Journal:  Blood Rev       Date:  2013-09-02       Impact factor: 8.250

7.  Wnt and Wnt inhibitors in bone metastasis.

Authors:  Joseph L Sottnik; Christopher L Hall; Jian Zhang; Evan T Keller
Journal:  Bonekey Rep       Date:  2012-07-04

8.  In vivo tumorigenesis was observed after injection of in vitro expanded neural crest stem cells isolated from adult bone marrow.

Authors:  Sabine Wislet-Gendebien; Christophe Poulet; Virginie Neirinckx; Benoit Hennuy; James T Swingland; Emerence Laudet; Lukas Sommer; Olga Shakova; Vincent Bours; Bernard Rogister
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

Review 9.  Adipose, Bone, and Myeloma: Contributions from the Microenvironment.

Authors:  Michelle M McDonald; Heather Fairfield; Carolyne Falank; Michaela R Reagan
Journal:  Calcif Tissue Int       Date:  2016-06-24       Impact factor: 4.333

10.  Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents.

Authors:  Deepti Soodgupta; Haiying Zhou; Wissam Beaino; Lan Lu; Michael Rettig; Mark Snee; James Skeath; John F DiPersio; Walter J Akers; Richard Laforest; Carolyn J Anderson; Michael H Tomasson; Monica Shokeen
Journal:  J Nucl Med       Date:  2016-01-07       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.